IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. Rev Mal Respir. 2018 Sep 19;: Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M Abstract BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-small cell lung cancer (NSCLC). METHODS: This phase II study is designed to administrate three durvalumab IV infusions (10mg/kg at day 1, 15, 29) before surgery, to patients with pathologically confirmed NSCLC, clinical stage IB (>4cm) or stage II, ≥18 years of age, WHO performans status 0-1, without selection on PD-L1 expression. Preoperative chemotherapy and radiation therapy are not permitted. The primary objective is feasibility of complete surgical resection. Major pathological response on surgical tissue, defined as 10% or less remaining tumor cells, will be a secondary objective. Additional secondary objectives include tolerance, adverse effects, delay between start of treatment and surgery, response rate (RECIST 1.1)...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research

Related Links:

Conclusion T4 stage patients had worse survival in N2 group. To get a more precisely stratification, skip metastasis and number of involved lymph node stations should be considered in future N stage classification. 
 DOI: 10.3779/j.issn.1009-3419.2020.01.03
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusion The expression of TRIM59 is closely related to the prognosis of NSCLC patients, and it is an independent risk factor for NSCLC patients. DOI: 10.3779/j.issn.1009-3419.2020.01.04
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered. 
 DOI: 10.3779/j.issn.1009-3419.2020.01.09
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusion Anlotinib effectively controlled the growth of NSCLC and improved TAO related symptoms. Anlotinib maybe normalize disordered growth of blood vessels through the VEGF signaling pathway, rather than simply inhibiting angiogenesis. 
 DOI: 10.3779/j.issn.1009-3419.2020.01.10
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Dai D, Xu WG, Wang Q, et al. Zhongguo Fei Ai Za Zhi, 2017, 20(12): 852-856. In the version of this article initially published, error appeared on page 853. The last sentence in part 2.2 should be “74%的患者经过达克替尼治疗后达到了部分缓解水平”. DOI: 10.3779/j.issn.1009-3419.2020.01.11
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
This study is registered with ClinicalTrials.gov (NCT02108964); enrolment to phase 1 is complete and the study is ongoing.FindingsBy Aug 31, 2017, 180 patients (116 [64%] women; median age 60 years (52–69); 116 [64%] with ECOG performance status 1) received nazartinib across seven dose levels: 75 mg (n=17), 100 mg (n=38), 150 mg (n=73), 200 mg (n=8), 225 mg (n=28), 300 mg (n=5), and 350 mg (n=11). Seven dose-limiting toxicities were observed in six (3%) patients who received 150 mg, 225 mg, or 350 mg nazartinib once daily. Although the maximum tolerated dose was not met, the recommended phase 2 dose was declared as 1...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: Available online 15 January 2020Source: The Lancet Respiratory MedicineAuthor(s): Jacek Jassem, Rafał Dziadziuszko
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
This spotlight audit investigates the efficacy and outcomes of molecular testing in patients with advanced non-small-cell lung cancer (NSCLC) in England covering 1,157 patients.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Rapid communication Source Type: research
. Howells Curcumin has been investigated extensively for cancer prevention, but it has been proposed that long-term treatments may promote clonal evolution and gain of cellular resistance, potentially rendering cancer cells less sensitive to future therapeutic interventions. Here, we used long-term, low-dose treatments to determine the potential for adverse effects in non-small cell lung cancer (NSCLC) cells. IC50s for curcumin, cisplatin, and pemetrexed in A549, PC9, and PC9ER NSCLC cells were evaluated using growth curves. IC50s were subsequently re-assessed following long-term, low-dose curcumin treatment and a thre...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Radiation Therapy | Respiratory Medicine | Study